Moderna will submit its coronavirus vaccine for regulatory approval on Monday, the company said — the second leading drug to pass the milestone this month.
The Massachusetts biotech firm said it will ask the Food and Drug Administration for emergency use authorization after completing its Phase 3 trial, finding the vaccine was 94.1 percent effective against Covid-19.
Moreover, Moderna said the vaccine was 100 percent effective at preventing severe cases of the disease.
